Lead Product(s) : Ataciguat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Rancho Santa Fe Bio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : This agreement provides RSF Bio with Sanofi’s rights to Ataciguat. With this license, RSF Bio will have the rights it needs to continue development of Ataciguat through clinical trials in the United States and potentially in select international countr...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 17, 2021
Lead Product(s) : Ataciguat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Rancho Santa Fe Bio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Ataciguat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ataciguat for Slowing Progression of Moderate Calcific Aortic Valve Stenosis
Details : Ataciguat is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Aortic Valve Stenosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 03, 2025
Lead Product(s) : Ataciguat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable